Status:
TERMINATED
Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
Lead Sponsor:
AUSL Romagna Rimini
Conditions:
COVID-19
Eligibility:
All Genders
18-100 years
Brief Summary
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered su...
Eligibility Criteria
Inclusion
- patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously
- Age\> 18 years
- Pneumonia diagnosed with Chest X-ray / or Chest CT
Exclusion
- Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04348448
Start Date
February 1 2020
End Date
September 1 2020
Last Update
July 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ausl della Romagna
Ravenna, Italy, 48121